Is SVRA or TAK more undervalued in 2026?

CirclFi compares Savara, Inc. (SVRA) and Takeda Pharmaceutical Company L (TAK) using 13 institutional-grade valuation models. SVRA has a Quality of Company score of 4.5/10 while TAK scores 7.4/10.

Which is a better buy — SVRA or TAK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SVRA and TAK valuations compare?

SVRA at $5.20 and TAK at $15.96 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SVRA vs TAK Valuation Comparison 2026 — Intrinsic Value Analysis

SVRA

Pharmaceutical Preparations

Savara, Inc.

Quality

4.5

out of 10

Value Trap

LOW

Price

$5.20

Last close

Models

7/13

Active

TAK

Pharmaceutical Preparations

Takeda Pharmaceutical Company L

Quality

7.4

out of 10

Value Trap

LOW

Price

$15.96

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	SVRA Fair Value	SVRA Upside	TAK Fair Value	TAK Upside
Bayesian DCF	Intrinsic	$1.39	-73.3%	$36.57	+129.1%
Earnings Power Value	Intrinsic	—	—	$21.77	+36.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.40	-92.3%	$13.54	-15.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SVRA vs TAK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SVRA vs TAK — Which Stock Is More Undervalued?

TAK scores higher with a 7.4/10 quality rating vs SVRA's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Savara, Inc. (SVRA) and Takeda Pharmaceutical Company L (TAK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SVRA currently trades at $5.20 with a QOC of 4.5/10, while TAK trades at $15.96 with a QOC of 7.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).